Home/Filings/4/0001562180-24-001988
4//SEC Filing

Leonard Frank X 4

Accession 0001562180-24-001988

CIK 0001645113other

Filed

Feb 28, 7:00 PM ET

Accepted

Feb 29, 4:38 PM ET

Size

14.4 KB

Accession

0001562180-24-001988

Insider Transaction Report

Form 4
Period: 2024-02-27
Leonard Frank X
EVP, Pres., Novocure Oncology
Transactions
  • Sale

    Ordinary Shares

    2024-02-28$16.14/sh2,078$33,545162,617 total
  • Award

    Ordinary Shares

    2024-02-27$16.30/sh+102,249$1,666,659164,695 total
  • Award

    Stock Options (Right to buy)

    2024-02-27$16.30/sh+156,348$2,548,472156,348 total
    Exercise: $16.30From: 2025-02-27Exp: 2034-02-26Ordinary Shares (156,348 underlying)
Footnotes (3)
  • [F1]Represents restricted share units that are scheduled to vest in equal installments on February 27, 2025, 2026 and 2027, subject to the reporting person's continued employment through such dates.
  • [F2]Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
  • [F3]Options to buy 156,348 ordinary shares will vest in equal installments on each of February 27, 2025, 2026, 2027 and 2028, subject to the reporting person's continued employment through such dates.

Issuer

NovoCure Ltd

CIK 0001645113

Entity typeother

Related Parties

1
  • filerCIK 0001822879

Filing Metadata

Form type
4
Filed
Feb 28, 7:00 PM ET
Accepted
Feb 29, 4:38 PM ET
Size
14.4 KB